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Abstract 
Chemotherapy  with  cyclophosphamide,  dox-
orubicin,  vincristine,  and  prednisone  (CHOP)
has  long  been  a  standard  treatment  for  lym-
phoma. Improvements to the efficacy of this reg-
imen can be made by increasing the doses of dox-
orubicin  and  cyclophosphamide,  as  in  the
chemotherapeutic  regimen  of  doxorubicin,  cy-
clophosphamide, vindesine, bleomycin, and pred-
nisone (ACVBP), and by reducing the standard
dosing interval, as seen with the CHOP-14 reg-
imen. Adding the immunotherapeutic agent rit-
uximab (R) to either CHOP or ACVBP has been
shown to improve outcomes significantly, such
that six cycles of R-CHOP plus two cycles of ritux-
imab are as effective as eight cycles of R-CHOP,
and R-CHOP-21 appears to be at least as effective
as the more dose-intense R-CHOP-14. In patients
who have several adverse prognostic factors, R-
ACVBP plus autologous stem-cell transplantation
has been shown to produce good treatment out-
comes. The use of positron emission tomography
scanning before and early in treatment should
allow  prediction  of  long-term  outcomes,  and
therefore  the  adaptation  of  treatment  to  indi-
vidual prognosis and treatment needs. In patients
with  follicular  lymphoma,  rituximab  has  been
shown to improve the efficacy of conventional
chemotherapies. In addition, rituximab alone or
yttrium-90-ibritumomab  tiuxetan  are  effective
maintenance therapies in this condition. 
Introduction
There are now about 90 defined subtypes of
lymphomas, and the clinical outcomes are dif-
ferent for the different subtypes, although many
cannot  currently  be  easily  distinguished.1 Ini-
tially, lymphomas were classified by clinical fac-
tors, which allowed clinicians to distinguish those
that had a good prognosis from those that had a
poor prognosis. More recently, molecular signa-
tures associated with prognosis have been identi-
fied.2For example, the germinal center B-cell-like
(GCB) subtype of diffuse large B-cell lymphoma
(DLBCL) was found to have a significantly better
survival rate than the non-GCB DLBCL. However,
such gene profiling is not yet possible as a clinical
routine, so the search is ongoing for a clinical
surrogate to identify these subtypes. 
Improving on the efficacy 
of CHOP 
The standard regimen of cyclophosphamide,
doxorubicin,  vincristine,  and  prednisone
(CHOP) given over a 3-weekly cycle (CHOP-
21) was easy to use and produced acceptable
response rates. However, it did not provide a
long-term survival benefit for most patients –
only about 40% of patients had long-term dis-
ease control.3 Several attempts were therefore
made to improve on the efficacy of this reg-
imen, using conventional chemotherapy. 
Treatment  with  doxorubicin,  cyclophos-
phamide,  vindesine,  bleomycin,  and  pred-
nisone (ACVBP)-14, in which the doses of both
doxorubicin and cyclophosphamide are higher
than in the standard CHOP regimen, was orig-
inally devised as a standard treatment for all T-
cell lymphomas. In two studies, there was a
significant  improvement  in  favor  of  ACVBP,
compared with CHOP-21, in patients who were
older and had a poor prognosis,4 and in those
who were young and had a good prognosis,5 al-
though ACVBP was more toxic than CHOP. In a
third study, ACVBP was shown to be more ef-
fective than methotrexate, bleomycin, doxoru-
bicin, cyclophosphamide, vincristine, and dex-
amethasone (m-BACOD) in patients with low-
risk aggressive lymphoma.6
Increasing the dose intensity of CHOP by re-
ducing  the  dose  interval  from  3  to  2  weeks
(CHOP-14) produced a clear increase in effi-
cacy in both young and elderly patients.7,8 An-
other study investigated the efficacy of ACVBP
followed  by  either  sequential  high-dose
chemotherapy or intensive chemotherapy plus
autologous  bone  marrow  transplant,  in  pa-
tients  with  a  high  International  Prognostic
Index (IPI). Bone marrow transplant was asso-
ciated  with  64%  overall  survival  in  the  long
term.9 Thus, this was the level of response and
efficacy  that  could  be  produced  in  patients
with a poor prognosis, prior to the introduction
of rituximab therapy. 
Treatment with R-CHOP 
The first demonstration that rituximab plus
CHOP  (R-CHOP)  was  more  effective  than
CHOP  alone  was  obtained  after  the  initial  2
years of the Groupe d’Étude des Lymphomes de
l’Adulte  (GELA)  LNH98.5  study.10 Long-term
follow-up of this study over 7 years (and now 10
years) has shown that the advantages are main-
tained, in terms of event-free, progression-free,
disease-free, and overall survival.11 This superi-
ority of R-CHOP over CHOP was subsequently
confirmed in other studies: the MInT study in
young patients with good prognosis,12 the RI-
COVER study in elderly patients,13 the British
Columbia study in patients with advanced dis-
ease,14 and the Eastern Cooperative Oncology
Group  study  in  elderly  patients,  which  also
demonstrated the efficacy of rituximab mainte-
nance  therapy.15 The  RICOVER  study  also
showed that six cycles of CHOP-14 plus eight in-
fusions of rituximab were as effective as eight
cycles of R-CHOP-14.13
A final research question remained about
the relative efficacies of the 2- versus 3-week
R-CHOP  regimens  (R-CHOP-14  versus R-
CHOP-21), as these had not been compared di-
rectly.  The  interim  results  of  the  LNH03-6B
study have been presented in abstract form,16
and showed no significant difference between
the two regimens, and a somewhat higher effi-
cacy and lower toxicity for the less dose-in-
tense R-CHOP-21. A second interim analysis,
recently  presented  at  the  11th International
Conference  on  Malignant  Lymphoma,  con-
firmed these results.17
Improving on the efficacy 
of R-CHOP 
The efficacies of R-ACVBP and R-CHOP were
compared  in  the  LNH03-2B  study  (clinical-
trials.gov identifier NCT00140595), which in-
volved young patients with DLBCL and an age-
adjusted IPI of 1. An interim analysis showed
superiority of R-ACVBP-14 over R-CHOP-21 in
terms of 2-year event-free survival. The final
analysis, recently presented at the 52nd Amer-
ican Society of Hematology Annual Meeting in
December 2010, confirmed a significant advan-
tage for R-ACVBP at 3 years in terms of event-
free, progression-free, disease-free, and overall
survival.18
There is little evidence for how best to treat
patients with 2-3 adverse prognostic factors, al-
though historically outcomes have been poor. A
retrospective  analysis  of  patients  with  DLBCL
treated with R-CHOP showed that response rates
were good for patients with 0-2 adverse prog-
nostic factors, but 4-year progression-free sur-
vival and overall survival rates were only just over
50% for patients with more than two adverse
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treat patients (with IPIs of 2-3) were given four
cycles of R-ACVBP, followed by carmustine, etopo-
side, cytarabine, and melphalan (BEAM) and au-
tologous stem-cell transplantation.20After 4 years
of follow-up, progression-free survival was high
at 76% (Figure 1), and there was no difference in
outcomes between groups of patients with two or
three adverse prognostic factors.20 In order to
compare ACVBP regimens with and without rit-
uximab, a matched control study was conducted
between two trials (LNH98-3B and LNH03-3B),
which showed a large difference in favor of the
rituximab-containing regimen.20 The results in-
dicate that treatment efficacy can be improved
for these patients with IPIs of 2-3, and that an in-
tensive  treatment  regimen  may  provide  them
with a probability of about 75% of living without
relapse. 
Adapting treatment to individual
patient risk 
An initial study of the use of [18F]fluoro-2-
deoxy-D-glucose  positron  emission  tomography
(PET) before treatment, after two cycles, and after
four cycles showed that it was possible to identify
those patients who were PET-negative early in
treatment, and thereby to predict with a high de-
gree of accuracy those who would remain disease-
free (Figure 2).21 Further studies have refined
these assessment methods, to reduce the inci-
dence of false-positives and help develop standard-
ized techniques and criteria that can be widely
used.22 Based on these initial results, a Phase II
study (LNH2007-3B) has been started to follow
PET  changes  under  two  treatment  regimens,
namely R-CHOP-14 and R-ACVBP-14, in patients
with DLBCL and an age-adjusted IPI of 2-3.23 PET
scans will be performed at baseline, and after two
and four cycles, and treatment adapted after cycle
4 depending on the PET results.
Treatment of follicular 
lymphoma 
Follicular  lymphoma  usually  grows  and
spreads  slowly,  and  has  few  symptoms.  The
current goal of therapy is to maintain the best
quality of life for patients and to treat them
only when they develop symptoms. Any thera-
peutic  approach  should  demonstrate  an  im-
provement in patient survival but, because me-
dian survival is 14-15 years, surrogate markers
such as progression-free survival are needed
to assess possible survival benefits. 
Randomized trials clearly demonstrated that
the addition of rituximab to the commonly used
chemotherapies  increased  patient  response
rates  and  survival.24-27 Therefore,  these  pa-
tients should receive rituximab in addition to
chemotherapy. Two studies have also investi-
gated the effects of maintenance therapy in pa-
tients who responded to initial treatment. One
reported  the  use  of  yttrium-90-ibritumomab
tiuxetan  versus no  further  treatment  for  pa-
tients who showed a complete or partial remis-
sion,  and  showed  an  advantage  for  mainte-
nance  treatment  over  the  watch-and-wait
strategy.28 A second study (PRIMA), completed
in 2007, included 1193 patients, 74% of whom
had  received  previous  R-CHOP  and  23%  of
whom  had  received  previous  rituximab,  cy-
clophosphamide,  vincristine,  and  prednisone
(R-CVP).27 The results were in favor of ritux-
imab maintenance therapy, compared with ob-
servation alone. After a median follow-up of 36
months,  progression-free  survival  was  74.9%
among those receiving rituximab versus 57.6%
in the observation group (P<0.0001).27
Conclusions 
CHOP has long been the standard therapy
for lymphoma. Improvements have been made
to the efficacy of this regimen by increasing
the dosing frequency, increasing the doses (in
the ACVBP regimen), and by adding rituximab
immunotherapy to either of these regimens.
Research is now underway to investigate the
place of new therapies such as lenalidomide,
new  immunotherapies,  and  high-dose  ritux-
imab  in  improving  patients’  overall  survival
(see Burchardt in this supplement). 
Figure 2. Examples of sequential [18F]fluoro-2-deoxy-D-glucose positron emission tomogra-
phy (PET) findings in two patients.21 Panels A-C show scans from a patient with truly nega-
tive early PET, predicting complete response. Panels D-F show scans from a patient with truly
positive early PET, predicting relapse. Arrows show hilar foci after two (panel E) and four
(panel F) cycles of chemotherapy. The Kaplan-Meier plot shows 2-year estimates of event-free
survival (EFS) according to early PETstatus after two cycles of chemotherapy.21From Haioun
C et al.[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggres-
sive  lymphoma:  an  early  prognostic  tool  for  predicting  patient  outcome.  Blood
2005;106:1376-81. Reprinted with permission from the American Society of Hematology via
the Copyright Clearance Center and the authors. 
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Figure 1. Progression-free
survival (PFS) in 208 hard-
to-treat  patients  (with  an
International  Prognostic
Index of 2-3) with diffuse
large  B-cell  lymphoma,
who were given four cycles
of rituximab, doxorubicin,
cyclo  phosphamide, vinde-
sine, bleomycin, and pred-
nisone  (R-ACVBP),  fol-
lowed  by  carmustine,
etoposide, cytarabine, and
melphalan  (BEAM)  and
autologous stem-cell trans-
plantation  (unpublished
data).  Intention-to-treat
population.[Hematology Reports 2011; 3(s3):e3] [page 9]
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